Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
Will you consider PD-L1 expression to estimate the likelihood of response to neoadjuvant chemotherapy in ER positive/HER-2 negative breast cancer after results of the Keynote-756?
Related Questions
What are your top takeaways from ESMO 2023?
How would you discuss the prognosis of HR-positive early breast cancer in an elderly >90 patient who elects against surgery in favor of endocrine treatment only?
When deciding whether to use ovarian function suppression in premenopausal patients with triple positive (ER+ HER2+) tumors, does HER2 status or response to neoadjuvant influence your decision?
Does the degree of hormone receptor positivity influence your decision to perform Oncotype testing?
Is any hormonal monitoring necessary for males with breast cancer on adjuvant aromatase inhibitor and LHRH agonist (Lupron)?
What estimated absolute benefit level of adjuvant chemotherapy for HR-pos HER2-negative breast cancer is worth recommending chemotherapy to patients?
Would you avoid chemotherapy in a postmenopausal woman age >65 with T3 HR+/HER2 negative with Oncotype DX < 25?
How would you approach surveillance imaging for men with early-stage, hormone receptor-positive breast cancer after unilateral mastectomy?
In which scenarios do you stage breast cancer using CT and nuclear bone scans versus PET-CT?
Do you follow LFTs in patients on tamoxifen as suggested in the prescribing guidelines? If so, how often do you check?
